# CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT01881867** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 54 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Stage IV Prostate Cancer

## Interventions

- **BIOLOGICAL:** Glycosylated Recombinant Human Interleukin-7
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01881867
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-10
- **Primary completion:** 2017-05-15
- **Final completion:** 2018-01-02
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2019-07-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01881867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01881867, "CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01881867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*